Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD®) Device [INP104, POD-DHE] in Patients With Migraine Headache

NCT03557333 is registered in ClinicalTrials.gov with Impel Pharmaceuticals as lead sponsor.

NCT NCT03557333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03557333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study of Safety and Tolerability of Chronic Intermittent Usage for 24 or 52 Weeks of Intranasal Dihydroergotamine Mesylate (DHE) Administered Using the I123 Precision Olfactory Delivery (POD®) Device [INP104, POD-DHE] in Patients With Migraine Headache
Lead sponsor
Impel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
July 13, 2018
Completion date
March 17, 2020
Enrollment
360 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

migraine headache